Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving
combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of giving combination
chemotherapy together with bevacizumab and to see how well it works in treating patients with
advanced neuroendocrine tumors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Sanofi